Q-omics provides the consensus-scored OR9L1P profile across patient tissues and cancer cell-line models. OR9L1P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, OR9L1P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, OR9L1P RNA expression shows 6,121 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, HNSC, and STAD as cancer lineages where OR9L1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR9L1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR9L1P survival associations across molecular data types. OR9L1P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR9L1P RNA expression–survival associations across cancer types. High OR9L1P expression shows unfavorable associations in THCA, LGG and SKCM, but favorable associations in OV, KIRC and LUSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .021). Together, the overview and detailed table identify OV as the clearest survival context for OR9L1P RNA expression.
This table summarizes OR9L1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR9L1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR9L1P shows higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher OR9L1P RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .003).
This table shows molecular features associated with OR9L1P in patient tissues and cancer cell lines. In patient samples, OR9L1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
